XML 67 R47.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Product Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Revenue from Contract with Customer [Abstract] |
Schedule of Net Product Sales | The following table summarizes total collaboration revenue recognized for the years ended December 31, 2024, 2023 and 2022:
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
Revenue from Collaborators | $ |  | $ |  | $
Research and development service revenue | — |  |  | 79,431 |  |  | 46,822 |
Right to access intellectual property revenue | — |  |  | 104,477 |  |  | 104,994 |
Material rights revenue | — |  |  | 71,980 |  |  | — |
Other | 30,695 |  |  | 13,039 |  |  | 9,493 |
Total | 30,695 |  |  | 268,927 |  |  | 161,309 |
The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December 31, 2024, 2023 and 2022:
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
| $ |  | $ |  | $
Research and development service revenue | — |  |  | 72,278 |  |  | 39,655 |
Other 1 | 2,113 |  |  | 5,067 |  |  | 9,493 |
Total | 2,113 |  |  | 77,345 |  |  | 49,148 |
1 Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration. The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December 31, 2024, 2023 and 2022:
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
| $ |  | $ |  | $
Research and development service revenue | — |  |  | 7,153 |  |  | 7,167 |
Right to access intellectual property revenue | — |  |  | 104,477 |  |  | 104,994 |
Material rights revenue | — |  |  | 71,980 |  |  | — |
Other 2 | 18,259 |  |  | 8,859 |  |  | — |
Total | 18,259 |  |  | 192,469 |  |  | 112,161 |
2 Represents revenue generated under the broad markets marketing and promotion agreement in conjunction with the collaboration. The table below presents the Company’s net product sales for the years ended December 31, 2024, 2023 and 2022.
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
| $ |  | $ |  | $
Product revenue - gross | 4,786,744 |  |  | 2,718,969 |  |  | 1,438,440 |
Less: Rebates and sales returns | (1,007,198) |  |  | (529,117) |  |  | (183,828) |
Product revenue - net | 3,779,546 |  |  | 2,189,852 |  |  | 1,254,612 |
The following table disaggregates net product revenue by product for the years ended December 31, 2024, 2023 and 2022.
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
| $ |  | $ |  | $
BRUKINSA® | 2,644,226 |  |  | 1,290,396 |  |  | 564,651 |
Tislelizumab | 620,836 |  |  | 536,620 |  |  | 422,885 |
XGEVA® | 224,403 |  |  | 92,828 |  |  | 63,398 |
BLINCYTO® | 74,331 |  |  | 54,342 |  |  | 36,107 |
KYPROLIS® | 66,171 |  |  | 39,799 |  |  | 13,696 |
POBEVCY® | 53,509 |  |  | 56,547 |  |  | 38,124 |
REVLIMID® | 36,028 |  |  | 76,018 |  |  | 79,049 |
Other | 60,042 |  |  | 43,302 |  |  | 36,702 |
Total product revenue - net | 3,779,546 |  |  | 2,189,852 |  |  | 1,254,612 |
Schedule of Accrued Sales Rebates and Returns | The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December 31, 2024 and 2023.
| Rebates, Returns and Other Deductions |  | Contra AR Accruals |  | Total
| $ |  | $ |  |
Balance at December 31, 2022 | 41,817 |  |  | 8,580 |  |  | 50,397 |
Amounts charged against product revenue | 275,031 |  |  | 254,086 |  |  | 529,117 |
Payments and credits | (176,912) |  |  | (232,231) |  |  | (409,143) |
Balance at December 31, 2023 | 139,936 |  |  | 30,435 |  |  | 170,371 |
Amounts charged against product revenue | 491,756 |  |  | 515,442 |  |  | 1,007,198 |
Payments and credits | (396,092) |  |  | (495,178) |  |  | (891,270) |
Balance at December 31, 2024 | 235,600 |  |  | 50,699 |  |  | 286,299 |

X
- Definition Schedule of Accrued Sales Rebates and Returns Current [Table Text Block] + References No definition available. + Details
Name: | bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock
Namespace Prefix: | bgne_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration